Semax

Semax 10 mg is a synthetic heptapeptide offered by SARMs Revolution Lab for laboratory research in Canada. Published literature describes Semax as an analogue containing the ACTH(4-7) fragment followed by Pro-Gly-Pro.

Semax 10 mg research product information

Sequence, concentration and batch documentation should be checked independently. The commercial vial should not be assumed equivalent to a formulation studied elsewhere.

What is Semax?

Semax is discussed in neuropeptide research involving neurotrophin expression, stress models and cerebral-ischaemia experiments. Rat studies have reported changes in BDNF, TrkB and related gene expression after experimental exposure.

These molecular and animal findings support research questions; they do not establish improved memory, focus, mood, stroke treatment or neuroprotection for this SRL product.

What does published Semax research show?

Several frequently cited papers involve rats or isolated cells. Older human reports from Russian-language clinical settings have examined acute ischaemic stroke, but designs, formulations and health-system context limit generalization. They should not be converted into treatment claims or self-use guidance.

Researchers should separate binding and gene-expression studies from controlled clinical efficacy. This page does not provide dosage, nasal administration, reconstitution, diagnosis or treatment instructions.

Semax status and evidence limits in Canada

A compound investigated or used in another jurisdiction is not automatically an authorized Canadian drug. Product identity, indication and regulatory status must be verified independently.

Semax 10 mg frequently asked questions

What is the published Semax sequence?

The literature describes Met-Glu-His-Phe-Pro-Gly-Pro, an ACTH-fragment analogue.

How much Semax is supplied?

The SRL listing identifies one 10 mg vial. Confirm the label and batch documentation.

Is the BDNF evidence human clinical proof?

No. Much of the best-known BDNF work was conducted in rats or cell models.

Does Semax research prove better memory or focus?

No guaranteed cognitive outcome is established for this commercial vial.

Does this page provide a nasal or injection protocol?

No. It provides product and scientific context only.

Where can related neuropeptide research be viewed?

See the Selank research page and the SRL peptide category.

Scientific references

• Semax binding and BDNF protein research in rat basal forebrain. 2006.
• Semax, BDNF and TrkB expression in rat hippocampus. 2006.
• Older comparative clinical report in acute ischaemic stroke. 1999.

Research-use notice: Semax 10 mg is offered strictly for laboratory research and analytical work. It is not intended for human consumption, self-administration, diagnosis, treatment or veterinary use.